Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma by J. Bousquet et al.
Bousquet et al. Clin Transl Allergy            (2019) 9:16  
https://doi.org/10.1186/s13601-019-0252-0
REVIEW
Guidance to 2018 good practice: ARIA 
digitally-enabled, integrated, person-centred 
care for rhinitis and asthma
J. Bousquet1,2,3,4* , A. Bedbrook1, W. Czarlewski5, G. L. Onorato1, S. Arnavielhe6, D. Laune6, E. Mathieu‑Dupas6, 
J. Fonseca7, E. Costa8, O. Lourenço9, M. Morais‑Almeida10, A. Todo‑Bom11, M. Illario12, E. Menditto13, 
G. W. Canonica14, L. Cecchi15, R. Monti16, L. Napoli17, M. T. Ventura18, G. De Feo19, W. J. Fokkens20, 
N. H. Chavannes21, S. Reitsma20, A. A. Cruz22, J. da Silva23, F. S. Serpa24,25, D. Larenas‑Linnemann26, 
J. M. Fuentes Perez27, Y. R. Huerta‑Villalobos27, D. Rivero‑Yeverino28, E. Rodriguez‑Zagal28, A. Valiulis29,30, 
R. Dubakiene31, R. Emuzyte32, V. Kvedariene33, I. Annesi‑Maesano34, H. Blain35,36, P. Bonniaud37, I. Bosse38, 
Y. Dauvilliers39,40, P. Devillier41, J. F. Fontaine42, J. L. Pépin43,44, N. Pham‑Thi45, F. Portejoie1, R. Picard46, 
N. Roche47, C. Rolland48, P. Schmidt‑Grendelmeier49, P. Kuna50, B. Samolinski51, J. M. Anto52,53,54,55, 
V. Cardona56, J. Mullol57,58, H. Pinnock59, D. Ryan60, A. Sheikh61, S. Walker62, S. Williams63, S. Becker64, 
L. Klimek65, O. Pfaar66, K. C. Bergmann67,68, R. Mösges69,70, T. Zuberbier67,68, R. E. Roller‑Wirnsberger71, 
P. V. Tomazic72, T. Haahtela73, J. Salimäki74, S. Toppila‑Salmi73, E. Valovirta75, T. Vasankari76, B. Gemicioğlu77, 
A. Yorgancioglu78, N. G. Papadopoulos79,80, E. P. Prokopakis81, I. G. Tsiligianni61,82, S. Bosnic‑Anticevich83, 
R. O’Hehir84,85, J. C. Ivancevich86, H. Neffen87, M. E. Zernotti88, I. Kull89,90, E. Melén90, M. Wickman91, C. Bachert92, 
P. W. Hellings3,93,94, G. Brusselle95, S. Palkonen96, C. Bindslev‑Jensen97, E. Eller97, S. Waserman98, L. P. Boulet99, 
J. Bouchard100, D. K. Chu101, H. J. Schünemann101, M. Sova102, G. De Vries103,104, M. van Eerd103,104, I. Agache105, 
I. J. Ansotegui106, M. Bewick107, T. Casale108, M. Dykewick109, M. Ebisawa110, R. Murray111,112, R. Naclerio113, 
Y. Okamoto114, D. V. Wallace115 and The MASK study group
Abstract 
Aims: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA‑LR of Montpellier, 
France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity 
across the life cycle, whatever their gender or socio‑economic status, in order to reduce health and social inequities 
incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change 
the management strategy in chronic diseases.
Methods: MASK implements ICT technologies for individualized and predictive medicine to develop novel care 
pathways by a multi‑disciplinary group centred around the patients.
Stakeholders: Include patients, health care professionals (pharmacists and physicians), authorities, patient’s associa‑
tions, private and public sectors.
Results: MASK is deployed in 23 countries and 17 languages. 26,000 users have registered.
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Clinical and
Translational Allergy
*Correspondence:  jean.bousquet@orange.fr 
1 MACVIA‑France, Fondation Partenariale FMC VIA‑LR, CHU Arnaud de 
Villeneuve, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier 
Cedex 5, France
Full list of author information is available at the end of the article
Page 2 of 19Bousquet et al. Clin Transl Allergy            (2019) 9:16 
Introduction
In all societies, the burden and cost of allergic and 
chronic respiratory diseases (CRDs) is increasing rap-
idly. Most economies are struggling to deliver modern 
health care effectively. There is a need to support the 
transformation of the health care system for integrated 
care with organizational health literacy. MASK (Mobile 
Airways Sentinel Network) [1] is a new development of 
the ARIA (Allergic Rhinitis and its Impact on Asthma) 
initiative [2, 3]. It works closely with POLLAR (Impact 
of Air POLLution on Asthma and Rhinitis, EIT Health) 
[4], and collaborates with professional and patient 
organizations in the field of allergy and airway diseases. 
MASK proposes real-life care pathways (ICPs) centred 
around the patient with rhinitis and/or asthma multi-
morbidity. It uses mHealth monitoring of environmen-
tal exposure and considers biodiversity. With the help 
of three EU projects (DigitalHealthEurope, Eurifi and 
Vigour) recently accepted on the digital transforma-
tion of health, MASK proposes a second change man-
agement strategy. The first one was the ARIA change 
management associated with the recognition and wide 
acceptance by all stakeholders of the essential links 
between rhinitis and asthma. The second one deals 
with change management of care pathways for rhinitis 
and asthma [5].
In the context of implementing communication on the 
digital transformation of health and care, specifically in 
relation to chapter  5 of the document “Digital tools for 
citizen empowerment and for person-centred care”, DG 
SANTE has taken steps towards supporting the scaling-
up and wider implementation of good practices in the 
field of  digitally-enabled, integrated, person-centred 
care. This work was carried out in collaboration with the 
newly-established Commission Expert Group, the “Steer-
ing Group on Health Promotion, Disease Prevention and 
Management of Non-Communicable Diseases”.
For this purpose, DG SANTE—in collaboration with 
the Commission’s Joint Research Centre—organized a 
“marketplace” workshop with  the Joint Research Cen-
tre in Ispra, the third biggest European Commission site 
after Brussels and Luxembourg. The aim of this workshop 
was for representatives from Member States and other 
countries participating in the 3rd Health Programme to 
learn more about the 10 good practices and key policy 
initiatives  in the domain of digitally-enabled, integrated, 
person-centred care, with a view to possible transfer and 
replication of the presented practices.
The current paper reviews the questions raised during 
the workshop concerning the good practice on allergic 
rhinitis and asthma: ARIA digitally-enabled, integrated, 
person-centred care for rhinitis and asthma multimor-
bidity using real-world evidence [1]. This practice is a 
GARD (Global Alliance against Chronic Respiratory Dis-
eases) demonstration project.
The practice
The practice includes the care pathways defined in 2014 
[6–8] (Fig. 1) as well as ICT (Information and Commu-
nication Technology) solutions (cell phones for patients, 
inter-operable tablets for health care professionals and 
a web-based questionnaire for physicians) [1, 9] (Fig. 2). 
The aim is to develop a change management strategy for 
chronic diseases [5].
MASK is a patient-centred ICT system [8]. A mobile 
phone app (the Allergy Diary, now called MASK-air), 
central to MASK, is available in 23 countries. It has 
been validated [10] and found to be an easy and effec-
tive method of assessing the symptoms of allergic rhini-
tis (AR) and work productivity [10–13]. MASK follows 
the checklist for the evaluation of Good Practices 
developed by the European Union Joint Action JA-
CHRODIS (Joint Action on Chronic Diseases and Pro-
moting Healthy Ageing across the Life Cycle) [14]. One 
of the major aims of MASK is to provide care pathways 
[15] in rhinitis and asthma multimorbidity [16] includ-
ing a sentinel network using the geolocation of users 
[17]. It can also inform the App users of the pollen and/
or pollution risk level in their area, by means of geolo-
cation (Table 1).
The practice has been developed for allergic rhinitis 
(and asthma multimorbidity), being the most common 
chronic disease globally [18, 19] and affecting all age 
groups from early childhood to old age. There are sev-
eral unmet needs that should be addressed in an ICP. 
Moreover, the lessons learnt will benefit all chronic 
EU grants (2018): MASK is participating in EU projects (POLLAR: impact of air POLLution in Asthma and Rhinitis, EIT 
Health, DigitalHealthEurope, Euriphi and Vigour).
Lessons learnt: (i) Adherence to treatment is the major problem of allergic disease, (ii) Self‑management strategies 
should be considerably expanded (behavioural), (iii) Change management is essential in allergic diseases, (iv) Educa‑
tion strategies should be reconsidered using a patient‑centred approach and (v) Lessons learnt for allergic diseases 
can be expanded to chronic diseases.
Keywords: App, Asthma, Care pathways, MASK, mHealth, Rhinitis, DG Santé
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diseases since rhinitis is considered as a mild disease 
although it impairs social life, school and work produc-
tivity considerably [20]. It is estimated that, in the EU, 
work loss accounts for 30–100 b€ annually. Moreover, 
it is essential to consider mild chronic diseases and to 
establish health promotion and management strategies 
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Fig. 1 Care pathways for chronic respiratory diseases. From [6–8]
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early in life in order to prevent a severe outcome and to 
promote healthy ageing [21].
Level of care integration
MASK is used for the integration of primary and spe-
cialist care, of primary-secondary-tertiary health 
care, as well as of health and social care for disease 
management.
Deployment
Many of the GPs that are developed in one region 
(country) take into account health systems, availability 
of treatments and legal considerations which makes it 
difficult to scale up the practice without customiza-
tion. MASK has taken the opposite direction starting 
with a tool immediately available in 10 languages and 
14 countries and regularly scaled up. Moreover, the tool 
is included in a generic ICP (Fig. 2) that can be custom-
ized easily in any country globally.
Geographical scope of the practice
MASK was developed in English and is currently avail-
able in 23 countries and 17 languages (Table 2).
New countries
Deployment is in process in Bolivia, Colombia, Japan 
and Peru. The involvement of developing countries is 
needed to offer a practice for middle- and low-income 
countries that will benefit poverty areas of developed 
countries and that will be in line with the mission of 
GARD. Deployment to the US is being discussed with 
the National Institute for Allergy and Infectious dis-
eases (NIH).
Transfer of innovation of allergic rhinitis and asthma 
multimorbidity in the elderly (MASK Reference Site Twinning, 
EIP on AHA)
The EIP on AHA includes 74 Reference Sites. The aim 
of this TWINNING is to transfer innovation from the 
MASK App to other reference sites. The phenotypic 
characteristics of rhinitis and asthma multimorbidity in 
adults and the elderly have been compared using vali-
dated mHealth tools (i.e. the Allergy Diary and CARAT 
[22]) in 23 Reference Sites or regions across Europe, 
Argentina, Australia, Brazil and Mexico [23].
Individuals/institutions reached
ARIA has been implemented in over 70 countries glob-
ally [3], and several governments use the practice. 
Approximately 26,000 users have registered to the MASK 
database. 700 patients have been enrolled in the Twin-
ning. Due to privacy, there is no possibility of assessing 
users who have reported data.
Timeframe
The project was initiated in 1999 during a World Health 
Organization (WHO) workshop (ARIA) and undergoes 
continuous developments. The ARIA initiative, com-
menced during a WHO workshop in 1999 [2], has been 
further developed by the WHO Collaborating Center 
Table 1 The ICT solution
App (MASK‑air) deployed in 23 countries: TRL9 (Technology Readiness 
level), Electronic clinical decision support system (ARIA e‑CDSS): TRL 7, 
e‑physician questionnaire deployed in 16 countries: TRL9
MASK‑air good practice [1, 14]
  5‑year work
  App: 26,000 users, 23 countries, 17 languages
  GDPR including geolocation [105]
  GP of the EIP on AHA, follows CHRODIS [14]
  Based on 11 EU grants (MeDALL [106],  GA2LEN [107]) including—in 
2018—POLLAR [4], VIGOUR, DigitalHealthEurope and Euriphi
  From a validated “research”  tool (2004‑2018) to large scale deploy‑
ment (2019–)
    Validation with COSMIN guidelines [40]
    Baseline characteristics [12]
    Work productivity [41, 42]
    EQ‑5D [43]
    Novel phenotypes of allergic diseases [44]
    Adherence to treatment and novel approaches to inform the efficacy 
of treatment [45].
  Patient’s organizations and scientific societies involved
  GARD (WHO alliance)
  Presented during WHO and EU ministerial meetings
  Next‑generation care pathways meeting (Dec 3, 2018) with the EIP on 
AHA, POLLAR (EIT Health) and GARD
  47 MASK papers in 12 languages [99, 108, 109]
  Dissemination according to the EIP on AHA [26]
Transfer of innovation (TWINNING [110])
  Interoperable platform with MASK
  25 RS plus Argentina, Australia, Brazil, Canada, Mexico [99, 108, 109]
  700 patients enrolled
  GDPR solutions being solved
ARIA e‑CDSS [9, 111]
  Interoperable platform with MASK
  Based on an expert meeting
  Electronic version available
  GDPR solutions being solved
Developments
  App for home services
  App for sleep
  App for COPD
  App for other chronic diseases
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for Asthma and Rhinitis (2002–2013). The initial goals 
(Phase 1) were (1) to propose a new AR classification, (2) 
to promote the concept of multimorbidity in asthma and 
rhinitis and (3) to develop guidelines with all stakeholders 
that could be used globally for all countries and all popu-
lations. ARIA has been disseminated and implemented 
in over 70 countries [3, 19, 24–32]. It was developed as a 
guideline [19] using the GRADE approach [33–39].
MASK, the Phase 3 ARIA initiative, is focusing on 
(1) the implementation of multi-sectoral care pathways 
(2) using emerging technologies (3) with real world 
data (4) for individualized and predictive medicine (5) 
in rhinitis and asthma multimorbidity (6) by a multi-
disciplinary group or by patients themselves (self-care) 
using the AIRWAYS ICPs algorithm (7) across the life 
cycle [8, 17]. It will be scaled up using the EU EIP on 
AHA strategy [26].
Phase 4 began in 2018. It concerns “change man-
agement” and includes the impact of air pollution in 
asthma and rhinitis (EIT Health 2018–2019: POLLAR, 
Impact of Air POLLution in Asthma and Rhinitis) [4] 
as well as the digital transformation of health and care 
(DigitalHealthEurope, Euriphi and Vigour).
Developments for 2019 include a multimorbidity App 
and the deployment of an app for home services.
The MASK project is intended to be sustainable and a 
business plan has been initiated.
The medium-term future is to develop care pathways 
for the prevention and control of chronic diseases to 
sustain planetary health. A symposium during the Finn-
ish Presidency of the EU Council is planned for October 
2019.
Scientific evidence and conceptual framework 
for configuring the practice
The scientific evidence is based on a validated “research” 
tool (The Allergy Diary, –2018) that has led to large scale 
deployment (MASK-air, 2019–):
• Validation of the app using COSMIN guidelines [40].
• Baseline characteristics informed [12].
• Work productivity associated with the control of 
allergic diseases [41, 42].
• EQ-5D is available and has been found to correlate to 
baseline characteristics [43].
• Novel phenotypes of allergic diseases have been dis-
covered [44].
Table 2 List of countries using MASK-air
AR Argentina, AT Austria, AU Australia, Be Belgium, BR Brazil, CA Canada, CH Switzerland, CZ Czech Republic, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, 
GB Great Britain, GR Greece, IT Italy, LT Lithuania, MX Mexico, NL The Netherlands, PL Poland, PT Portugal, SE Sweden, TR Turkey
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• Adherence to treatment is extremely low and novel 
approaches to inform the efficacy of treatment have 
been proposed [45] leading to novel studies for a bet-
ter understanding of guidelines [46, 47].
Evidence of impact
MASK has identified novel phenotypes of allergic dis-
eases [44] that have been confirmed in classical epide-
miologic studies by re-analyzing them [48–51]. One of 
the studies used the MASK baseline characteristics [49]. 
These phenotypes allowed the re-classification of allergic 
multimorbidity and the discovery of a new extreme phe-
notype of allergic diseases that need to be considered in 
the stratification of patients.
MASK has shown real-life mHealth data for the first 
time in allergy treatment in 9,950 users [1, 45]. This led 
to next-generation care pathways for allergic diseases 
(meeting co-organized by POLLAR, a member of EIT 
Health, EIP on AHA and GARD (WHO alliance): 3-12-
2018) and proposed a change management strategy [5].
MASK is involved in an EIT Health project (POLLAR) 
which assesses the interactions between air pollution, 
asthma and rhinitis [4].
With the EIP on AHA, MASK is involved in 3 EU pro-
jects on the digital transformation of health and care 
(DigiHealthEurope, Euriphi and Vigour).
MASK is also involved in a large project on Planetary 
Health in a side event which will take place during the 
Presidency of the EU council (Finland). This event will 
gather researchers, academic leaders and other experts 
from European institutions as well as other stakeholders 
and will discuss Planetary Health global challenges and 
their scientific solutions. Experts on human health as well 
as on effects of climate change, urbanization and food 
production will be invited to prepare a European ini-
tiative to promote effective and sustainable research on 
planetary health issues. The event similarly aims at rais-
ing political awareness about the need for multidiscipli-
nary and systemic approaches to Planetary Health issues 
globally and in the EU. The multimorbid App developed 
by MASK may be used in the project.
Contextual relevance
The practice addresses a public health priority
Chronic respiratory diseases (CRDs) are major non-com-
municable diseases (NCDs) [18]. Rhinitis and asthma 
multimorbidity is common and the two diseases should 
be considered jointly [19]. Asthma is the most com-
mon NCD in children and rhinitis is the most common 
chronic disease in Europe. They often start early in life, 
persist across the life cycle and cause a high disease 
burden in all age groups [19]. By 2020, rhinitis will affect 
at least 20% of the old age population [52–56]. These dis-
eases represent an enormous burden associated to medi-
cal and social costs and they impact health and social 
inequalities.
The practice is based on a local/regional/national strategic 
action plan
The Polish Presidency of the EU Council (3051st Coun-
cil Conclusions) made the prevention, early diagnosis 
and treatment of asthma and allergic diseases a priority 
to reduce health inequalities [57, 58]. The 3206th Cyprus 
Council Conclusions [59] recommended that the diag-
nosis and treatment of chronic diseases should be initi-
ated as early as possible to improve AHA. Debates at the 
European Parliament recommended the  early diagnosis 
and management of CRDs in order to promote active and 
healthy ageing (AHA) [60–62].
The practice is also a WHO-associated project: Initial 
workshop (1999), WHO Collaborating Center for rhi-
nitis and asthma (2004–2014), Global Alliance against 
Chronic Respiratory Diseases (GARD) [63, 64] demon-
stration project (2015–).
Unmet needs
Several unmet needs have been identified in aller-
gic diseases. They include (1) suboptimal rhinitis and 
asthma control due to medical, cultural and social bar-
riers [65, 66], (2) better understanding of endotypes 
[67], phenotypes and multimorbidities, (3) assessment 
of allergen and pollutants as risk factors to promote 
sentinel networks in care pathways, (4) stratification of 
patients for optimized care pathways [68] and (5) pro-
motion of multidisciplinary teams within integrated 
care pathways, endorsing innovation in clinical trials 
and encouraging patient empowerment [17, 69].
Overall goal
The general objective of AIRWAYS-ICPs [6–8] is  to 
develop multi-sectoral ICPs for CRDs used across Euro-
pean countries and regions in order to (1) reduce the 
burden of the diseases in a patient-centred approach, 
(2) promote AHA, (3) create a care pathways simula-
tor tool which can be applied across the life cycle and 
in older adults, (4) reduce health and social inequali-
ties, (5) reduce gender inequalities, (6) use the lessons 
learned in CRDs for chronic diseases and (7) promote 
SDG3 (more specifically 3.4) (https ://www.who.int/
sdg/targe ts/en/). In September 2015, the UN General 
Assembly established the Sustainable Development 
Goals (SDGs), a set of global goals for fair and sustain-
able  health at every level from planetary biosphere to 
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local community [70, 71], essential for  sustainable 
development. SDG  3 prioritizes health and well-being 
for all ages.
The aim of AIRWAYS-ICPs is  also to generalise the 
approach of the uniform definition of severity, con-
trol and risk of severe asthma presented to WHO [66] 
and allergic diseases [72] in order to develop a uniform 
risk stratification usable for chronic diseases in most 
situations.
MASK further refined AIRWAYS ICPs using mobile 
technology to promote the digital transformation of 
health and care in developed and developing countries 
for all age groups.
Target population
In the initial phase, the target population included all 
patients with allergic rhinitis and asthma multimorbid-
ity. Rhinitis and asthma are considered as a model for 
all chronic diseases and the project is being extended to 
chronic diseases.
All patients able to use a smartphone (≥ 12  years) 
represent the target population. A special effort is being 
placed in underserved populations from developing 
countries as the practice is a GARD (Global Alliance 
against Chronic Respiratory Diseases, WHO alliance) 
demonstration project.
Stakeholders involved
Involvement in the design, implementation (including 
the creation of ownership), evaluation, continuity/
sustainability
As from the very first workshop in 1999, the ARIA ini-
tiative has included all stakeholders required to develop 
a WHO programme on CRDs (GARD). In particular, 
patient’s organizations were involved. All health care pro-
fessionals were also involved (physicians, primary care, 
pharmacists, other health care professionals). Another 
important component of ARIA was the deployment to 
developing countries [73]. Moreover, policy makers were 
also actively involved.
ARIA has grown regularly over the past 20  years and 
an ARIA chapter is ongoing in over 70 countries in all 
continents with a very active scaling up strategy [26]. 
MASK has used the ARIA working group to scale up the 
practice.
All stakeholders were highly receptive
The ARIA and now the MASK community is very cohe-
sive and all members are extremely reactive. They have 
been particularly active in deploying MASK in the 23 
countries and we have received requests from many 
other countries in which MASK-air is not yet available.
Resistance or conflict of interest: None
Implementation methodology/strategy
We used the scaling up strategy of the European Innova-
tion Partnership on Active and Healthy Ageing and pro-
posed a 5‐step framework for developing an individual: 
(1) what to scale up: (1‐a) databases of good practices, 
(1‐b) assessment of viability of the scaling up of good 
practices, (1‐c) classification of good practices for local 
replication and (2) how to scale up: (2‐a) facilitating 
partnerships for scaling up, (2‐b) implementation of key 
success factors and lessons learnt, including emerging 
technologies for individualized and predictive medicine. 
This strategy has already been applied to the chronic res-
piratory disease action plan of the European Innovation 
Partnership on Active and Healthy Ageing [26].
Consistency in the pace of delivery
For the past 20 years, ARIA has been a success story in 
over 72 countries [3, 8, 19, 24, 25, 27, 28, 30–32, 38, 46, 
74–100]. A Pocket Guide has been translated into 52 lan-
guages. MASK is following ARIA with the same group 
and the same strategy.
Main outcomes and evaluation of the practice
The ARIA strategy was to change management in the 
treatment of asthma and rhinitis since nasal symp-
toms—often the most troublesome—were not con-
sidered in most asthmatics. Over 85% of asthma in 
children and adolescents is associated with rhinitis, 
suggesting common pathways, whereas only 20–30% 
of rhinitis patients have asthma, suggesting rhinitis-
specific genes. There is a link between asthma sever-
ity and rhinitis multimorbidity. Asthma is more severe 
in patients with rhinitis [101]. The strategy at all levels 
of care indicates that it is essential to consider multi-
morbidity in the management of asthma for the ben-
efit of the patient and the satisfaction of the treatment 
as shown in many surveys (Fig.  3). Some studies have 
found that the ARIA strategy is more effective than 
free treatment choice [102]. Moreover, EMA has used 
the ARIA recommendations for the approval of a house 
dust mite immunotherapy tablet including asthma and 
rhinitis multimorbidity [103].
The change management strategy of MASK has 
not yet been evaluated. However, the results of the 
first studies indicate that the vast majority of patients 
are not adherent to treatment [45] and that next-
generation care pathways are needed (Figs.  4 and 5). 
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Next-generation care pathways were initiated in Paris, 
December 3, 2018, as part of POLLAR, MASK and 
GARD.
Additional (secondary) outcomes assessed
Work productivity and school performance are meas-
ured. When rhinitis and/or asthma are not well con-
trolled, work productivity is impaired [1, 41, 43].
Sustainability of the practice
The MASK App, The Allergy Diary, was used to demon-
strate the scientific value of the project [1]. It has been 
replaced by the commercial App, MASK-air, which is ver-
sion 3.0 and which includes questionnaires (e.g. tobacco 
and allergens) and sleep (VAS and Epworth questionnaire 
[104]) (Fig. 6). A business plan is in place for the sustain-
ability of the practice.
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Communication about the practice and dissemination 
of results
A communication strategy has been set up [1] and 
includes a website (mask-air.com), media coverage, leaf-
lets and newsletters, publications in scientific journals 
and lay press, partners’ networks and events. The MASK 
community includes over 300 members in all countries in 
which MASK is deployed.
Budget required to implement the practice
The budget required to implement the MASK strategy 
is around 1.5 M€. It will be provided by the private sec-
tor (1 M€) and from EU grants, in particular a Structural 
and Development Fund. POLLAR has an additive budget 
of 2 M€ to embed outdoor air pollution and aerobiology 
data in the ICP using artificial intelligence.
It is difficult to estimate human resources since many 
physicians worked in the 23 countries for the translation, 
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Fig. 5 Embedding air pollution and biodiversity in care pathways. From [4]
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adaptation of the practice and its implementation. It can 
be proposed that 50–100  h have been spent working in 
each country.
The practice has been presented to multiple national 
and international meetings.
Sustainability has been carefully evaluated and a busi-
ness plan is in place.
Main lessons learned
• Adherence to treatment is the major problem of 
allergic disease.
• Self-management strategies should be considerably 
expanded (behavioural).
• Change management is essential in allergic diseases.
• Education strategies should be reconsidered using a 
patient-centred approach.
• Lessons learned for allergic diseases can be expanded 
to chronic diseases.
Improvement and expansion of the practice
An expert meeting took place at the Pasteur Insti-
tute in Paris, December 3, 2018, to discuss next-
generation care pathways and lessons learnt (Fig.  7, 
Annex 1): (1) patient participation, health literacy and 
self-care through technology-assisted “patient acti-
vation”, (2) implementation of care pathways by phar-
macists and (3) next-generation guidelines assessing 
the recommendations of GRADE guidelines in rhinitis 
and asthma using real-world evidence (RWE) assessed 
by mobile technology. The meeting was organized by 
POLLAR and MASK in collaboration with GARD, 
patient’s organizations and all European scientific soci-
eties in the field.
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